Cleave Therapeutics

Cleave Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to targeting valosin-containing protein (VCP)/p97 as a novel target in cellular stress pathways essential for cancer cell growth and survival, such as the DNA damage response (DDR) and the response to proteotoxic stress.